Watch ATNM. Know when insiders buy.
One email the day a filing lands. Free.
ATNM
Actinium Pharmaceuticals, Inc.
1.03
−0.02 −1.90%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
56
WATCH · shorts 56
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $32.4MP/E 2.9DIV YIELD —FCF YIELD —REV TTM —NET INCOME $11.3MNET CASH $35.6M52W 0.75 – 1.69SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $35M | — | — | $27.6M | $27.9M | — | 0.89 | −$5.2M | $478K | −$5.7M | Aug 7 |
| Q1 2026 · Mar 31 | — | — | — | −$5.9M | −$5.5M | — | -0.18 | −$5.9M | $2K | −$5.9M | Aug 7 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$6.4M | −$5.9M | — | -0.19 | −$5.3M | — | — | Mar 30 |
| Q3 2025 · Sep 30 | $90K | — | — | −$5.7M | −$5.1M | — | -0.16 | −$6.3M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$7.5M | −$6.9M | — | -0.22 | −$5.4M | — | — | Aug 7 |
| Q1 2025 · Mar 31 | — | — | — | −$16.6M | −$15.9M | — | -0.51 | −$7.6M | — | — | Aug 7 |
| Q4 2024 · Dec 31derived | — | — | — | −$7.5M | −$6.7M | — | -0.21 | −$5.8M | $0 | −$5.8M | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$12.6M | −$11.6M | — | -0.37 | −$12M | $0 | −$12M | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$12.4M | −$11.4M | — | -0.38 | −$8M | $0 | −$8M | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$9.6M | −$8.7M | — | -0.31 | −$7.4M | $11K | −$7.4M | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$10.3M | −$9.3M | — | -0.33 | −$7.5M | $0 | −$7.5M | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$14.4M | −$13.3M | — | -0.49 | −$11.1M | $30K | −$11.2M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $90K | — | −$36.2M | −$33.9M | -37652.2% | -1.09 | −$24.6M | $104K | −$24.7M | — | — |
| FY2024 · to Dec 31 | — | — | −$42.1M | −$38.2M | — | -1.27 | −$33.1M | $11K | −$33.1M | — | — |
| FY2023 · to Dec 31 | $81K | — | −$51.9M | −$48.8M | -60269.1% | -1.83 | −$47.3M | $153K | −$47.5M | — | — |
| FY2022 · to Dec 31 | $1M | — | −$34.1M | −$33M | -3205.5% | -1.37 | $8.6M | $366K | $8.3M | — | — |
| FY2021 · to Dec 31 | $1.1M | 21.3% | −$25M | −$24.8M | -2165.6% | -1.20 | −$20.9M | $133K | −$21M | — | — |
| FY2020 · to Dec 31 | — | — | −$22.4M | −$22.2M | — | -1.83 | −$21.6M | $253K | −$21.9M | — | — |
Every number comes from Actinium Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.